603998.SH
方盛制药
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 9.70
−2.32%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.8B | 1.7B | 1.8B | 1.6B | 1.8B |
| Cost of Revenue | 480.4M | 489.5M | 500.4M | 519.5M | 586.3M |
| Gross Profit | 1.3B | 1.3B | 1.3B | 1.1B | 1.2B |
| Operating Expenses | |||||
| R&D Expense | 158.8M | 154.5M | 139.2M | 107.9M | 70.4M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 158.1M | 153.4M | 145.8M | 149.3M | 187.7M |
| Selling & Marketing Expense | 626.1M | 603.5M | 702.9M | 657.5M | 754.6M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 988.7M | 957.2M | 1.0B | 954.9M | 1.1B |
| Cost and Expenses | 1.5B | 1.4B | 1.5B | 1.5B | 1.6B |
| Operating Income (EBIT) | 362.6M | 358.2M | 285.3M | 196.4M | 332.0M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 357.7M | 353.2M | 286.0M | 203.3M | 326.6M |
| Income Tax Expense | 55.9M | 50.6M | 36.1M | 23.7M | 49.9M |
| Bottom Line | |||||
| Net Income | 306.5M | 306.4M | 255.2M | 186.8M | 285.9M |
| Earnings from Cont. Ops | 301.8M | 302.6M | 249.8M | 179.6M | 276.7M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 306.5M | 306.4M | 255.2M | 186.8M | 285.9M |
| Per Share | |||||
| Basic EPS | CN¥0.70 | CN¥0.70 | CN¥0.59 | CN¥0.43 | CN¥0.66 |
| Diluted EPS | CN¥0.70 | CN¥0.70 | CN¥0.58 | CN¥0.42 | CN¥0.66 |
| Revenue Per Share | CN¥4.05 | CN¥3.99 | CN¥4.11 | CN¥3.75 | CN¥4.14 |
| Shares | |||||
| Basic Shares Outstanding | 442.0M | 437.7M | 432.6M | 434.5M | 433.1M |
| Diluted Shares Outstanding | 442.0M | 437.7M | 432.6M | 434.5M | 433.1M |
| Profitability Metrics | |||||
| EBITDA | — | 442.6M | 367.6M | 275.5M | 411.5M |
| D&A | — | 84.5M | 82.2M | 79.1M | 79.5M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026